Similarly, elevated TMEM16A expression in the breast cancer and ovarian granulosa cells can induce ERK1/2 phosphorylation, while knockdown of TMEM16A or pharmacological inhibition of the channel activity reduces ERK1/2 activation [21, 35]. This evidence concerns the gene MAPK3 and breast cancer.